<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957086</url>
  </required_header>
  <id_info>
    <org_study_id>IHN01</org_study_id>
    <nct_id>NCT00957086</nct_id>
  </id_info>
  <brief_title>Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head &amp; Neck Cancer</brief_title>
  <official_title>Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head &amp; Neck Squamous Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innogene Kalbiotech Pte. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to improve the loco-regional control rate and overall survival of&#xD;
      locally advanced head and neck squamous carcinoma (HNSCC). The investigators hypothesize that&#xD;
      the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both&#xD;
      epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold&#xD;
      standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after&#xD;
      resection of their locally advanced HNSCC will confer therapeutic advantage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to improve the loco-regional control rate and overall survival of&#xD;
      locally advanced head and neck squamous carcinoma (HNSCC). We hypothesize that the addition&#xD;
      of nimotuzumab (a recombinant humanized murine immune antibody that blocks both epidermal&#xD;
      growth factor (EGF) and transforming growth factor (TGF)) to the current gold standard of&#xD;
      concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after resection&#xD;
      of their locally advanced HNSCC will confer therapeutic advantage. We have designed a phase&#xD;
      III randomized study that includes a placebo arm. We assume a 10% increase in 2 year disease&#xD;
      free survival (from 60% to 70%). To achieve statistical significance at 90% power, we&#xD;
      calculate the need for 355 patients per arm, assuming also a 10% dropout rate. We aim to&#xD;
      accomplish this study with the involvement of a multidisciplinary team of surgical, radiation&#xD;
      and medical oncologists actively involved in the management of HNSCC coming from multiple&#xD;
      institutions and spanning at least 12 different countries. For quality assurance we will have&#xD;
      the involvement of Singapore Clinical Research Institute who will lead the data coordination&#xD;
      and ensure fidelity of data collected and statistical analysis; the European Society of&#xD;
      Therapeutic Radiation Oncology (EQUAL-ESTRO) for radiation dose and fields and an&#xD;
      international independent panel of medical oncologist, radiation oncologist and&#xD;
      biostatistician for the Data Monitoring Committee (DMC). This committee will monitor&#xD;
      significant events and advise on continuation or termination of trial. Concurrent with the&#xD;
      randomized trial, we will be collecting bio specimens including blood, tumour and saliva,&#xD;
      pre-treatment and on completion of surgical resections. We hypothesize that there are&#xD;
      important biomarkers including clusters of genes, cancer stem cells that will predict&#xD;
      prognosis and treatment response. The analyses performed will be very powerful because of the&#xD;
      large sample size, the specimens are collected prospectively and because the statistical&#xD;
      analyses will be multivariate, incorporating not only treatment but biological and staging&#xD;
      data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the disease-free survival between patients randomized to adjuvant nimotuzumab/cisplatin/RT with the control arm</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the overall survival between the two arms</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the Toxicity Profile between the 2 arms</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">710</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comprising Adjuvant Cisplatin, Concurrent RT and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.</description>
    <arm_group_label>Nimotuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age should be greater than or equal to the minimum age of consent in the applicable&#xD;
             country&#xD;
&#xD;
          -  Histologically proven head and neck squamous cell cancer (excluding nasopharynx,&#xD;
             salivary glands, paranasal sinuses and unknown primaries) on biopsy of the primary&#xD;
             lesion or the neck mass.&#xD;
&#xD;
          -  Resectable stage III/IV according to the AJCC/UICC staging system with no evidence of&#xD;
             distant metastasis.&#xD;
&#xD;
          -  Complete macroscopic resection.&#xD;
&#xD;
          -  Patients should have at least one of the following pathological features for&#xD;
             inclusion: pT3 or pT4 and any nodal stage (N), except T3N0 of the larynx, with&#xD;
             negative resection margins, or a tumor stage of 1 or 2 with a nodal stage of 2 or 3&#xD;
             and no distant metastasis (M0); patients with stage T1 or T2 and N0 or N1 who had&#xD;
             unfavorable pathological findings (extranodal spread, positive resection margins,&#xD;
             perineural involvement, or vascular tumor embolism) are also eligible, as are those&#xD;
             with oral-cavity or oropharyngeal tumors with involved lymph nodes at level IV or V.&#xD;
&#xD;
          -  Performance status must be ECOG 0 or 1. Patients should be able to tolerate&#xD;
             chemotherapy and radiotherapy.&#xD;
&#xD;
          -  Adequate bone marrow, renal and hepatic function:&#xD;
&#xD;
               1. WBC&gt;3000/mm3, platelets&gt;100000/mm3&#xD;
&#xD;
               2. Serum creatinine&lt;upper limit of normal range as per institution and calculated&#xD;
                  creatinine clearance (according to the Cockcroft and Gault method) &gt;50 ml/min.&#xD;
&#xD;
               3. SAP, SGOT&lt;2 x upper limit of normal range, bilirubin &lt;1.5 x upper limit of normal&#xD;
                  range.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histology other than SCC or its subtype.&#xD;
&#xD;
          -  Patients with disease subsite deemed suitable for organ preservation approach, namely&#xD;
             stage III/IV laryngeal or hypopharyngeal carcinoma with not more than low-volume T4&#xD;
             disease; low-volume T4 disease is defined as disease not eroding into cartilage or&#xD;
             extending not more than 1 cm into the base of tongue.&#xD;
&#xD;
          -  Clinical or radiological evidence of distant metastasis.&#xD;
&#xD;
          -  Uncontrolled comorbidities such as diabetes mellitis, hypertension, cardiac disease.&#xD;
&#xD;
          -  Uncontrolled infection.&#xD;
&#xD;
          -  Uncontrolled hypercalcemia.&#xD;
&#xD;
          -  Prior history of cancer less than 5 years ago or a synchronous primary outside the&#xD;
             head and neck area.&#xD;
&#xD;
          -  Prior treatment, head and neck radiotherapy, chemotherapy or surgery (excluding&#xD;
             biopsy) or anti-EGFR therapy such as cetuximab/EGFR oral tyrosine kinase inhibitor.&#xD;
&#xD;
          -  Patients for whom compliance with follow-up is unlikely.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K C Soo, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>VIC 3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology and Radiobiology</name>
      <address>
        <city>Vedado</city>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria University School of Medicine</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital Bangalore</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Hrudayalaya Hospital (Mazumdar Shaw Cancer Institute)</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center Trivandrum, India</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cipto Mangunkusumo General Hospital Indonesia</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INHA University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pantai Medical Centre, Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahkota Medical Center</name>
      <address>
        <city>Melaka</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Fahad Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oncology Centre</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GVI Oncology</name>
      <address>
        <city>Panorama</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Med Univ Hosp [TMUH]</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute Bangkok (+Chulabhorn for RT)</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Cuba</country>
    <country>Egypt</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase III Adjuvant Concurrent Chemo-RT +/- nimotuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

